Related Experiment Video
Updated: May 31, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Which one among the Pt-containing anticancer drugs more easily forms monoadducts with G and A DNA bases? A
Marta E Alberto1, Valeria Butera, Nino Russo
1Dipartimento di Chimica, Università della Calabria,Via P. Bucci, cubo 14c, 87036 Arca vacata di Rende (CS), Centro di Calcolo ad Alte Prestazioni per Elaborazioni Parallele e Distribuite-Centro d'Eccellenza MIUR, Italy. malberto@unical.it
Abstract:
The platination processes of DNA bases with second- and third-generation Pt(II) anticancer drugs have been investigated using density functional theory (DFT) combined with the conductor-like dielectric continuum model (CPCM) approach, in order to describe their binding mechanisms and to obtain detailed data on the reaction energy profiles. Although there is no doubt that a Pt-N7 bond forms during initial attack, the energetic profiles for the formation of the monofunctional adducts are not known. Herein, a direct comparison between the rate of formation of the monofunctional adducts of the second- and third-generation anticancer drugs with guanine (G) and adenine (A) DNA bases has been made in order to spotlight possible common or different behavior. The guanine as target for platination process is confirmed to be preferred over adenine for all the investigated compounds and for both the hydrolyzed forms considered in our investigation. The preference for G purine base is dominated by electronic factors and promoted by a more favorable hydrogen-bonds pattern, confirming the important role played by H-bonds in determining both structural and kinetic control on the purine platination process.
Related Concept Videos
DNA Base Pairing
EDTA: Chemistry and Properties
Mutagenicity and Carcinogenicity
Base Excision Repair
The first step of...
Antiviral Nucleoside Inhibitors
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

